ScreenerHero

GTBP GT Biopharma, Inc.

NAS · US · Healthcare · Biotechnology · gtbiopharma.com
6.200USD-2.67%Mkt Cap: 11.19M $P/E: —

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Enga…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap11.19M USD
Enterprise Value6.53M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-28.35M USD
Revenue/Share—
Last Price6.200 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.59
PEG1.05
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.19
EPS (TTM)-151.15
EPS (Forward)-10.80
52W Range
4.9104% of range34.25
52W High34.25 USD
52W Low4.910 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-489.96%
ROA-349.79%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.91M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-79.31%
Net Debt-4.96M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio2.61
Quick Ratio2.23
Book Value/Sh2.00 USD
Cash/Share2.75 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateAug 21, 2017
Splits
Last Split1:25
Split DateSep 8, 2026
Analyst Consensus
Rating—
Target (Mean)75.00 USD
Upside (mean)+1109.7%
Target Range75.00 USD – 75.00 USD
# Analysts1
Ownership
Shares Out.1.80M
Float1.70M
Insiders15.67%
Institutions4.66%
Short Interest
Short Ratio2.6d
Short % Float14.23%
Short % Out.14.22%
Shares Short256.61K
Short (prev mo.)162.53K
Technical
SMA 507.320 (-15.3%)
SMA 20010.98 (-43.5%)
Beta0.85
S&P 52W Chg16.45%
Avg Vol (30d)77.67K
Avg Vol (10d)47.37K
Technical Indicators
RSI (14)42.9
MACD-0.3939
MACD Signal-0.3243
MACD Hist.-0.0696
BB Upper9.780 USD
BB Middle7.008 USD
BB Lower4.235 USD
BB Width79.13%
ATR (14)0.8020 USD
Vol Ratio (20d)0.17x